Get the Stockscreener App
8.305
2.41%
-0.205
Pre-market:
8.10
-0.205
-2.47%
Vor Biopharma Inc stock is traded at $8.305, with a volume of 387.00K.
It is down -2.41% in the last 24 hours and down -59.61% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$8.51
Open:
$8.41
24h Volume:
387.00K
Relative Volume:
0.64
Market Cap:
$181.97M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-5.064
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
+4.47%
1M Performance:
-59.61%
6M Performance:
+81.57%
1Y Performance:
-53.57%
1-Day Range:
$8.03
$8.49
1-Week Range:
$7.21
$8.66
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
8.305 | 186.46M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Will Vor Biopharma Inc. stock maintain momentum in 2025Gold Moves & Capital Efficiency Focused Strategies - Newser
What drives Vor Biopharma Inc stock priceEarnings Surprise Analysis & Superior Capital Trading Plans - earlytimes.in
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation? - Yahoo Finance
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Form 424B3 Vor Biopharma Inc. - StreetInsider
Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR) - MarketBeat
How Vor Biopharma Inc. stock benefits from global expansionLayoff News & Fast Exit and Entry Strategy Plans - BỘ NỘI VỤ
Wedbush Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know - sharewise.com
Wedbush Initiates Coverage on Vor Biopharma (VOR) with Neutral R - GuruFocus
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating - MarketScreener
Wedbush Assumes Vor Biopharma, Inc. (VOR) at Neutral - StreetInsider
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Vor Biopharma Inc. stock attract more institutional investorsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Why retail investors favor Vor Biopharma Inc. stock2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
What technical signals suggest for Vor Biopharma Inc. stockQuarterly Profit Summary & Verified Momentum Stock Alerts - newser.com
Combining price and volume data for Vor Biopharma Inc.2025 Big Picture & Technical Confirmation Alerts - newser.com
How currency fluctuations impact Vor Biopharma Inc. stockFed Meeting & Real-Time Buy Signal Alerts - newser.com
Can a trend reversal in Vor Biopharma Inc. lead to recoveryWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Using data models to predict Vor Biopharma Inc. stock movementJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - newser.com
Using Python tools to backtest Vor Biopharma Inc. strategiesJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Forecasting Vor Biopharma Inc. price range with options dataAnalyst Upgrade & Stepwise Trade Execution Plans - newser.com
Why Vor Biopharma Inc. stock could benefit from AI revolutionRisk Management & Real-Time Chart Breakout Alerts - newser.com
Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates - MSN
Can Vor Biopharma Inc. stock beat analyst upgrades2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
Risk adjusted return profile for Vor Biopharma Inc. analyzedTrade Exit Summary & Capital Efficient Trading Techniques - newser.com
Published on: 2025-11-16 14:39:57 - newser.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):